iBio grants 430,000 stock options to CMO

iBio, Inc. reported that its Chief Medical Officer, Molly Carr, received a grant of stock options covering 430,000 shares of common stock.

Rhea-AI Filing Summary

iBio, Inc. reported that its Chief Medical Officer, Molly Carr, received a grant of stock options covering 430,000 shares of common stock. The options have an exercise price of $1.40 per share and expire on July 30, 2036, with all 430,000 options held directly after the grant.

The award was granted on July 31, 2026 as an inducement award outside the iBio, Inc. 2023 Omnibus Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest 25% on the one-year anniversary of the grant date, with an additional 6.25% vesting every three months thereafter, contingent on Ms. Carr’s continued employment.

Insider Trade Summary

Grant/Award: 430,000 shares

Grant/Award 1 txn

Insider Carr Molly

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1, F2	430,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 430,000 contracts (Direct)

Footnotes (2)

1. F1. Stock option granted as an inducement award to the Reporting Person that was granted outside of the iBio, Inc. 2023 Omnibus Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) on July 31, 2026 (the "Grant Date").
2. F2. Vesting 25% on the one-year anniversary of the Grant Date, with an additional 6.25% vesting every three months thereafter, provided the Reporting Person remains employed by iBio, Inc. through each applicable vesting date.

Key Figures

Stock options granted: 430,000 shares Exercise price: $1.40 per share Options after transaction: 430,000 shares +2 more

5 metrics

Stock options granted 430,000 shares Grant to Chief Medical Officer on July 31, 2026

Exercise price $1.40 per share Exercise price for the 430,000 stock options

Options after transaction 430,000 shares Total derivative securities held directly following the grant

Initial vesting portion 25% Vests on the one-year anniversary of the July 31, 2026 grant date

Subsequent vesting tranche 6.25% Additional portion vesting every three months after the first anniversary

Key Terms

Stock Option (right to buy), inducement award, Nasdaq Listing Rule 5635(c)(4), 2023 Omnibus Incentive Plan, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

inducement award financial

"Stock option granted as an inducement award to the Reporting Person"

An inducement award is a special cash or equity payment given to a new hire—often an executive or key employee—outside the company’s regular pay plans to persuade them to join. Think of it like a signing bonus that can align the new person’s goals with shareholders but also represents a cost and can reduce existing owners’ percentage of the company, so investors watch these awards for their impact on ownership and future performance.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4) on July 31, 2026"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

2023 Omnibus Incentive Plan financial

"granted outside of the iBio, Inc. 2023 Omnibus Incentive Plan"

vesting financial

"Vesting 25% on the one-year anniversary of the Grant Date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did iBio (IBIO) report for Chief Medical Officer Molly Carr?

iBio reported that Chief Medical Officer Molly Carr received a grant of 430,000 stock options. The options are exercisable for iBio common stock at $1.40 per share, expiring on July 30, 2036, and are held directly by her.

What are the key terms of Molly Carr’s 430,000 iBio (IBIO) stock options?

The grant covers 430,000 options to purchase iBio common stock at an exercise price of $1.40 per share. The options expire on July 30, 2036 and were granted as compensation, with no cash paid for the award itself.

How do the iBio (IBIO) stock options granted to Molly Carr vest over time?

The options vest 25% on the one-year anniversary of the July 31, 2026 grant date. An additional 6.25% vests every three months thereafter, provided Molly Carr remains employed by iBio through each applicable vesting date.

Were Molly Carr’s iBio (IBIO) options granted under the 2023 Omnibus Incentive Plan?

No. The 430,000 stock options were granted as an inducement award outside the iBio, Inc. 2023 Omnibus Incentive Plan. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) on July 31, 2026.

How many iBio (IBIO) derivative securities does Molly Carr hold after this Form 4 transaction?

Following the reported grant, Molly Carr holds 430,000 stock options related to iBio common stock. These options represent the full amount acquired in this transaction and are reported as directly owned derivative securities after the award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/04/2026 - 04:02 PM Accepted by SEC EDGAR 08/04/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Molly

(Last) (First) (Middle)

C/O IBIO, INC.

11750 SORRENTO VALLEY ROAD, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$1.4	07/31/2026		A		430,000		07/31/2027(2)	07/30/2036	Common Stock	430,000	$0	430,000	D

Explanation of Responses:

1. Stock option granted as an inducement award to the Reporting Person that was granted outside of the iBio, Inc. 2023 Omnibus Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) on July 31, 2026 (the "Grant Date").

2. Vesting 25% on the one-year anniversary of the Grant Date, with an additional 6.25% vesting every three months thereafter, provided the Reporting Person remains employed by iBio, Inc. through each applicable vesting date.

	/s/ Marc Banjak, Attorney-in-Fact	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)